This presentation features testing overviews for container closures, pharmaceutical glass and plastic and covers common tests and techniques for each.
Once you have successfully encapsulated an (API), the next task is to characterize that product and understand its release kinetics, such that it can be labeled and prepared for subsequent studies. Following are some lessons learned from characterizing the end product.
The emulsion system created when forming microparticle can quickly become complex. Following are critical factors to consider when beginning work with microparticle formulation for a large protein molecule.
Securing a partner to serve as an extension of Janssen’s Biotherapeutics Development API-Large Molecule team was essential to reducing both risk and the time needed for delivery of critical clinical supplies.
By applying remote monitoring, advanced modeling, and optimization of manufacturing processes, Industry 4.0 offers process reliability and product quality through connecting machines and data.
Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
Watch this video to learn more about this manufacturing site capabilities, quality management systems, PPI implementation, product expansion, assurance of supply and lead times.
OptiForm® Solution Suite is a comprehensive offering which incorporates everything you need to progress your candidate from late-stage discovery to phase I.
A platform that combines drug development expertise and biomanufacturing and integrated services to offer advantages to ADC developers.
This webinar explores use cases showing how machine learning and analytics can help overcome the challenges facing the biopharma industry through more confident data-driven decisions.
Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.
With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.
Nitto Avecia Pharma Services' in-depth scientific expertise covers a diverse range of products, as well as a wide variety of dosage forms and routes of delivery. Nitto Avecia Pharma Services pre-formulation studies are designed with an anticipated formulation strategy, route of administration, and ultimate formulation configuration in mind. Our formulation experts unite a thorough understanding of your needs along with the data on the physicochemical properties of the compounds to ensure the delivery of a stable and robust product.
Supporting start-ups to globally recognized biotech companies, Nitto Avecia Pharma Services has the track record and knowledge to provide comprehensive support for biomolecules at all phases.
With over 10 years industry experience per structural scientist, Nitto Avecia Pharma Services’ strategic, systematic approach provides high quality solutions for identification, characterization, and development of highly sensitive methodologies.
